Oligodendroglioma Follow-up

Updated: Jan 02, 2015
  • Author: ABM Salah Uddin, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print
Follow-up

Further Outpatient Care

After initial appropriate management, closely monitor the patient with the family for tumor recurrence or chemotherapy-induced adverse effects. Monitor with regular follow-up care and MRI scans every 3 months initially and then every 6 months to 1 year.

Next:

Further Inpatient Care

After the initial surgical resection and rehabilitation, the patient may require further inpatient care depending on the development of complications from either therapy or tumor recurrence. Appropriate intervention also depends on the nature of complications (eg, surgery for recurrence, steroid therapy for increased vasogenic edema).

Previous
Next:

Inpatient & Outpatient Medications

Patients with seizures require appropriate seizure medications even after surgery. Over time, the dose of the medications can be reduced, depending on the frequency of seizures.

Previous
Next:

Transfer

Transfer depends on the residual neurological deficit. The patient may be fully ambulatory or may need appropriate transfer arrangements (eg, cane, wheelchair).

Previous
Next:

Complications

Closely observe the patient for any complications resulting from continuing treatment, such as radiation necrosis from radiation therapy or neuropathy from chemotherapy.

Previous
Next:

Prognosis

See the list below:

  • Combined loss of 1p/19q is a significant predictor of overall survival in anaplastic oligodendroglioma and is also significantly associated with longer recurrence-free survival and chemosensitivity.
  • The phosphatase and tensin homologue deleted by chromosome 10 ( PTEN) alteration is associated with a poor prognosis.
  • Other variables, including age of the patient at time of diagnosis, location and extent of surgical resection, postoperative performance status, histologic features of the tumor, and use of adjuvant therapies and early presentation with seizures, determine the prognosis for an individual patient. Overall, as many as three fourths of patients with nonanaplastic tumors can be expected to survive 5 years from the time of diagnosis, with a median reported survival duration of 6-10 years. For those with anaplastic oligodendrogliomas, median survival is more likely to be 3-4 years. Late progression of disease is common, so the usual 5-year survival time used to indicate "cure" in other cancers is not relevant for oligodendrogliomas.
Previous
Next:

Patient Education

Throughout the entire process, educate the patient and family through regular follow-up care and involvement of support groups to cope with physical, emotional, and spiritual stress. With proper education, the patient and family can develop good insight into the course and prognosis of the tumor.

Previous